Conexeu Sciences Inc.
No SEC Form 4 filings for $CNXU in the last 30 days.
See all $CNXU insider activity →Conexeu Sciences Inc. reported Q3 2026 results with $0 revenue and a net loss of $7.73M, or $(0.29) per share, widening from a $(1.30M) loss year-over-year. The company, listed on Nasdaq since May 2026, is scaling operations and advancing a biomaterial device for a planned FDA submission in Q1 2027.
Conexeu Sciences Inc. reported a wider net loss year-over-year due to higher operating costs after its Nasdaq listing. The company stated cash resources are insufficient for the next twelve months without new financing, attributing the increased expenses to marketing, business development, and personnel investments.
Conexeu Sciences Inc. (CNXU) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities From June 18, 2026 through September 4, 2026, Conexeu Sciences Inc. (the "Company") has issued an aggregate of 1,448,368 unregistered shares of common stock and 202,500 unregistered common stock purchase warrants pursuant to vario
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning CNXU (Conexeu Sciences Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent CNXU coverage spans technology, earnings and corporate actions.
The loss widening and zero revenue may pressure the stock lower in the short term.
Loss expansion and liquidity risk likely pressure CNXU stock lower.
Dilution of existing shareholders and potential short‑term price pressure.
Niche market narrative may sustain modest gains.
Preclinical milestone supports the company’s regenerative-aesthetics thesis, but it is not yet clinical or revenue-generating.
AlphAI scores every news story that mentions CNXU with an AI model for sentiment and relevance, and aggregates insider trades from Conexeu Sciences Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Conexeu Sciences Inc. reported Q3 2026 results with $0 revenue and a net loss of $7.73M, or $(0.29) per share, widening from a $(1.30M) loss year-over-year. The company, listed on Nasdaq since May 2026, is scaling operations and advancing a biomaterial device for a planned FDA submission in Q1 2027.
1 min readConexeu Sciences Inc. reported a wider net loss year-over-year due to higher operating costs after its Nasdaq listing. The company stated cash resources are insufficient for the next twelve months without new financing, attributing the increased expenses to marketing, business development, and personnel investments.
1 min readConexeu Sciences Inc. (CNXU) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities From June 18, 2026 through September 4, 2026, Conexeu Sciences Inc. (the "Company") has issued an aggregate of 1,448,368 unregistered shares of common stock and 202,500 unregistered common stock purchase warrants pursuant to vario
1 min readJourney Medical (DERM) rose 13% on strong Q2 results, with revenue up 23% to $18.5M. Iovance (IOVA) gained 11% on 66% revenue growth to $99.3M. Caris (CAI) advanced 8% after raising 2026 revenue guidance to $1.03B-$1.04B. Prelude (PRLD) up 8% on narrower Q2 loss. Compugen (CGEN) gained 7% on COM701 trial progress. Conexeu (CNXU) rose 4% on regenerative aesthetics market opportunity.
3 min readConexeu Sciences Inc. (CNXU) highlights a new category in medical aesthetics focused on tissue regeneration. Independent research estimates the bioregenerative-aesthetics market at $1.6B in 2025, growing 11% annually. Conexeu's CXU platform, an ECM-based collagen scaffold, has completed a 12-month preclinical study meeting objectives. The company aims to restore tissue structure rather than just replace volume.
6 min readBiotech Insider commentary highlights Conexeu Sciences (Nasdaq: CNXU), a preclinical company developing CXU and its Ten-Minute Tissue device that transitions from fluid to extracellular matrix gel in about 10 minutes. It plans a predicate-based 510(k) submission in early 2027. The piece also cites regenerative peers including Vericel (VCEL) with Q2 2026 revenue of $77.5M.
6 min readIPO Edge hosted a 30-minute fireside chat with Conexeu Sciences (Nasdaq: CNXU) CEO Miles Harrison. The preclinical regenerative tissue company discussed its ECM platform for wound care, aesthetics, oral health, and veterinary uses, including a bioresorbable scaffold for breast implants. It cited an anticipated FDA 510(k) submission in early 2027 and related catalysts.
4 min readConexeu Sciences Inc. (NASDAQ: CNXU) says its investigational CXU tissue-restoration platform targets large-volume injectable aesthetics, aiming to restore body volume after GLP-1 weight loss. The company completed a 12-month P.R.O.O.F. preclinical study in a large-volume model, with results not yet peer-reviewed. Boston Consulting Group projects GLP-1-related aesthetic provider revenue could rise to about $2.0B by 2030.
5 min readConexeu Sciences Inc. (Nasdaq: CNXU) says its preclinical CXU tissue-restoration platform targets large-volume body contouring needs created by GLP-1 weight loss. The company completed a 12-month P.R.O.O.F. preclinical study in small and large-volume models. Boston Consulting Group projects GLP-1-related aesthetic care revenue rising from about $0.7B to $2.0B by 2030.
5 min readConexeu Sciences Inc. (Nasdaq: CNXU) says it has completed a 12-month preclinical P.R.O.O.F. study for its CXU tissue-restoration scaffold, aimed at large-volume injectable aesthetics. The company cites growing aesthetics markets and GLP-1-driven demand, and targets a 510(k) submission in Q1 2027, pending further testing.
6 min read
